Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655015 | 0.83 | CYP2B6 (0.55) | NPC1RAB9APOLBRECQLGPR139 | |
| SCHEMBL4395908 | 0.77 | ALOX5 (0.46) | NPC1RAB9APOLBHPGDSMN1; SMN2 | |
| SCHEMBL4393402 | 0.77 | PGR (0.46) | NPC1RAB9AGPR139HPGDCES2 | |
| SCHEMBL4399935 | 0.76 | CYP2B6 (0.59) | NPC1RAB9APOLBRECQLGPR139 | |
| SCHEMBL4399515 | 0.75 | ERCC5 (0.49) | NPC1RAB9APOLBRECQLGPR139 | |
| SCHEMBL6059596 | 0.74 | SLC6A2 (0.55) | NPC1RAB9APOLBRECQLGPR139 | |
| SCHEMBL2632778 | 0.74 | CES2 (0.58) | NPC1RAB9APOLBRECQLGPR139 | |
| Hydrochloric Acid SCHEMBL30450072 | 0.73 | SLC6A2 (0.56) | NPC1RAB9APOLBRECQLGPR139 | |
| SCHEMBL4393537 | 0.73 | CYP2B6 (0.63) | NPC1RAB9AGPR139HPGDCYP2C19 | |
| SCHEMBL13754507 | 0.72 | TAS1R3 (0.66) | GPR139ERCC5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120219592-A1 | Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2012-08-30 | — | — | US | disclosed |
| US-8188150-B2 | Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain | BIOCOPEA LIMITED (GB) | 2012-05-29 | — | — | US | disclosed |
| US-20090306216-A1 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219592-A1 | Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | OPRL1, HRH3, HRH2 | NPC1 2030/4885RAB9A 3758/4885POLB 2540/4885 |
| US-20090306216-A1 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | OPRL1, HRH3, NR1H2 | NPC1 1313/4885RAB9A 3945/4885POLB 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.